William McCoull

The Francis Crick Institute — United Kingdom

Medicine · Health Sciences

24h-index2.1kcitations86works4.62yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cytokine Signaling Pathways and Interactions(24), Mathematical Biology Tumor Growth(22), Synthesis and Catalytic Reactions(10), Computational Drug Discovery Methods(9), Asymmetric Synthesis and Catalysis(8)

Publications86 total

AZ14289671 is a highly selective and blood-brain barrier penetrant irreversible TKI that targets EGFRExon20 insertions

Cell Reports Medicine·2025Open Access

The changing landscape of medicinal chemistry optimization

7 cited

Nature Reviews Drug Discovery·2025· 7 cited

Highly Optimized CNS Penetrant Inhibitors of EGFR Exon20 Insertion Mutations

5 cited

Journal of Medicinal Chemistry·2025· 5 cited

Optimization of Potent, Efficacious, Selective and Blood–Brain Barrier Penetrating Inhibitors Targeting EGFR Exon20 Insertion Mutations

3 cited

Journal of Medicinal Chemistry·2024· 3 cited

Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations

8 cited

Journal of Medicinal Chemistry·2024· 8 citedOpen Access

Figure S6 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

2023Open Access

Figure S5 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

2023Open Access

Figure S8 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

2023Open Access

Figure S9 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

2023Open Access

Figure S3 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

2023Open Access

Figure S11 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

2023Open Access

Supplementary Data_Clean from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

2023Open Access

Figure S11 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

2023Open Access

Figure S6 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

2023Open Access

Figure S10 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

2023Open Access

Figure S4 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

2023Open Access

Figure S7 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

2023Open Access

Figure S4 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

2023Open Access

Figure S9 from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

2023Open Access

Data from AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-xL, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia

2023Open Access

page 1 of 5Next →

Frequent Co-authors

Edward J. Hennessy(9), Franklin A. Davis(8), Paul D. Kemmitt(8), Graeme R. Robb(8), Eric T. Gangl(8), Martin J. Packer(8), Peter Barton(7), Kate F. Byth(7), Philip B. Rawlins(7), David Hargreaves(6), Piotr Raubo(6), Stephen E. Fawell(6), Srividya B. Balachander(6), Francis D. Gibbons(6), Shenghua Wen(6), Barry R. Davies(6), Jeffrey Varnes(6), Nicholas J. Newcombe(6), Andrew D. Ferguson(5), Michael Zinda(5)